

Appl. No. 09/881,823  
Amendment dated June 30, 2004  
Reply to Office Action of January 2, 2004

### I. AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

#### **Listing of Claims:**

Claims 1-24 (Cancelled)

Claim 25 (Currently Amended) A method for treating or preventing dental caries comprising administering to the oral cavity of a subject in need of such treatment a chimeric monoclonal antibody, wherein the chimeric antibody specifically binds to a cariogenic organism associated with dental caries and elicits a humoral immune response in the oral cavity of the subject to an antigen of the cariogenic organism including destruction of the cariogenic organism, wherein the portion of the chimeric monoclonal antibody that binds to the cariogenic organism is derived from a species other than that of the treated subject and wherein the portion of the constant region of the chimeric monoclonal antibody that triggers an effect of the humoral immune response is from the same species of the subject.

Claim 26. (Previously presented) The method of claim 25, wherein the cariogenic organism is *Streptococcus mutans*.

Claim 27. (Previously presented) The method of claim 25, wherein the chimeric monoclonal antibody includes a complementarity determining region of a monoclonal antibody that specifically binds to *S. mutans*.

Claim 28. (Previously presented) The method of claim 25, wherein the chimeric monoclonal antibody includes a complementarity determining region of a monoclonal antibody produced by a hybridoma deposited with the American Type Culture Collection as ATCC No. HB12559, which is designated SWLA1.

Appl. No. 09/881,823  
Amendment dated June 30, 2004  
Reply to Office Action of January 2, 2004

Claim 29. (Previously presented) The method of claim 25, wherein the variable region of the light chain of the chimeric monoclonal antibody comprises the amino acid sequence as shown in SEQ ID NO. 2.

Claim 30. (Previously presented) The method of claim 29, wherein the amino acid sequence is encoded by a nucleic acid sequence comprising SEQ ID NO. 1.

Claim 31. (Previously presented) The method of claim 25, wherein the variable region of the heavy chain of the chimeric monoclonal antibody comprises the amino acid sequence as shown in SEQ ID NO. 4.

Claim 32. (Previously presented) The method of claim 31, wherein the amino acid sequence is encoded by a nucleic acid sequence comprising SEQ ID NO. 3.

Claim 33. (Previously presented) The method of claim 25, wherein the chimeric monoclonal antibody includes a constant region of IgG antibody or IgM antibody.

Claim 34. (Previously presented) The method of claim 25, wherein the subject in need of such treatment is a human and the chimeric monoclonal antibody includes a constant region of human IgG antibody or IgM antibody.

Claim 35. (Previously presented) The method of claim 25, wherein the chimeric monoclonal antibody is a recombinant chimeric monoclonal antibody.

Claim 36. (Previously presented) The method of claim 25, wherein the chimeric monoclonal antibody is produced from a transgenic plant.

Claim 37. (Previously presented) The method of claim 25, wherein the subject in need of such treatment is a mammal.

Claim 38. (Previously presented) The method of claim 25, wherein the subject in need of such treatment is a human, dog, or cat.

Appl. No. 09/881,823  
Amendment dated June 30, 2004  
Reply to Office Action of January 2, 2004

Claim 39. (Previously presented) The method of claim 25, wherein the chimeric monoclonal antibody is administered orally.

Claim 40. (Currently Amended) A chimeric monoclonal antibody that specifically binds to a cariogenic organism and elicits a humoral immune response to an antigen of the cariogenic organism in the oral cavity of a subject that hosts the cariogenic organism, wherein the humoral immune response includes destruction of the cariogenic organism, wherein the portion of the monoclonal antibody that binds to the cariogenic organism is derived from a species other than that of the subject to be treated with said chimeric monoclonal antibody and wherein the portion of the constant region of the monoclonal antibody that triggers an effect of the humoral immune response is from the same species of the subject.

Claim 41. (Previously presented) The chimeric monoclonal antibody of claim 40, wherein the cariogenic organism is *S. mutans*.

Claim 42. (Previously presented) The chimeric monoclonal antibody of claim 40, wherein the portion of the monoclonal antibody that binds to the cariogenic organism includes a complementarity determining region of a monoclonal antibody that specifically binds to *S. mutans*.

Claim 43. (Previously presented) The chimeric monoclonal antibody of claim 40, wherein the portion of the monoclonal antibody that binds to the cariogenic organism includes a complementarity determining region of a monoclonal antibody produced by a hybridoma deposited with the American Type Culture Collection as ATCC No. HB12559, which is designated SWLA1.

Claim 44. (Previously presented) The chimeric monoclonal antibody of claim 40, wherein the variable region of the light chain of the antibody comprises the amino acid sequence as shown in SEQ ID NO. 2.

Claim 45. (Previously presented) The chimeric monoclonal antibody of claim 44, wherein the amino acid sequence is encoded by a nucleic acid sequence comprising SEQ ID NO. 1.

Appl. No. 09/881,823  
Amendment dated June 30, 2004  
Reply to Office Action of January 2, 2004

Claim 46. (Previously presented) The chimeric monoclonal antibody of claim 40, wherein the variable region of the heavy chain of the antibody comprises the amino acid sequence as shown in SEQ ID NO. 4.

Claim 47. (Previously presented) The chimeric monoclonal antibody of claim 46, wherein the amino acid sequence is encoded by a nucleic acid sequence comprising SEQ ID NO. 3.

Claim 48. (Previously presented) The chimeric monoclonal antibody of claim 40 having a constant region of IgG antibody or IgM antibody.

Claim 49. (Previously presented) The chimeric monoclonal antibody of claim 40, wherein the subject that hosts the cariogenic organism is a human and the chimeric monoclonal antibody includes a constant region of human IgG antibody or IgM antibody.

Claim 50. (Previously presented) The chimeric monoclonal antibody of claim 40 as a recombinant chimeric monoclonal antibody.

Claim 51. (Previously presented) The chimeric monoclonal antibody of claim 40 produced from a transgenic plant.

Claim 52. (Previously presented) The chimeric monoclonal antibody of claim 40, wherein the subject that hosts the cariogenic organism is a mammal.

Claim 53. (Previously presented) The chimeric monoclonal antibody of claim 40, wherein the subject that hosts the cariogenic organism is a human, dog, or cat.